Login to Your Account



ViroPharma's DuoCort Buy Hinges on Orphan Approval

By Mari Serebrov
Washington Editor

Friday, October 28, 2011

A lot is riding on the European approval of Plenadren. For patients with adrenal insufficiency, it could be the first innovative treatment in more than half a century. And for DuoCort Pharma AB, it could be a payday of up to nearly $165 million.

That's how much ViroPharma Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription